These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 16815871)

  • 21. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.
    Arimori K; Kuroki N; Hidaka M; Iwakiri T; Yamsaki K; Okumura M; Ono H; Takamura N; Kikuchi M; Nakano M
    Pharm Res; 2003 Jun; 20(6):910-7. PubMed ID: 12817897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein.
    Sugiyama Y; Kato Y; Chu X
    Cancer Chemother Pharmacol; 1998; 42 Suppl():S44-9. PubMed ID: 9750028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice.
    Iyer L; Ramírez J; Shepard DR; Bingham CM; Hossfeld DK; Ratain MJ; Mayer U
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):336-41. PubMed ID: 11914914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver.
    Tobin PJ; Hong Y; Seale JP; Rivory LP; McLachlan AJ
    J Pharm Pharmacol; 2005 Jan; 57(1):39-45. PubMed ID: 15638991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.
    Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
    Cancer Chemother Pharmacol; 1998; 42(4):280-6. PubMed ID: 9744772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat.
    Yang X; Hu Z; Chan SY; Goh BC; Duan W; Chan E; Zhou S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Jul; 821(2):221-8. PubMed ID: 15936253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The contribution of intestinal UDP-glucuronosyltransferases in modulating 7-ethyl-10-hydroxy-camptothecin (SN-38)-induced gastrointestinal toxicity in rats.
    Tallman MN; Miles KK; Kessler FK; Nielsen JN; Tian X; Ritter JK; Smith PC
    J Pharmacol Exp Ther; 2007 Jan; 320(1):29-37. PubMed ID: 17003228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11.
    Araki E; Ishikawa M; Iigo M; Koide T; Itabashi M; Hoshi A
    Jpn J Cancer Res; 1993 Jun; 84(6):697-702. PubMed ID: 8340259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats.
    Horikawa M; Kato Y; Sugiyama Y
    Pharm Res; 2002 Sep; 19(9):1345-53. PubMed ID: 12403072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of hesperidin on the pharmacokinetics of CPT-11 and its active metabolite SN-38 by regulating hepatic Mrp2 in rats.
    Wang X; Rao Z; Qin H; Zhang G; Ma Y; Jin Y; Han M; Shi A; Wang Y; Wu X
    Biopharm Drug Dispos; 2016 Oct; 37(7):421-432. PubMed ID: 27510985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats.
    Hu Z; Yang X; Ho PC; Chan E; Chan SY; Xu C; Li X; Zhu YZ; Duan W; Chen X; Huang M; Yang H; Zhou S
    Pharm Res; 2005 Jun; 22(6):902-14. PubMed ID: 15948034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human multidrug resistance associated protein 4 confers resistance to camptothecins.
    Tian Q; Zhang J; Tan TM; Chan E; Duan W; Chan SY; Boelsterli UA; Ho PC; Yang H; Bian JS; Huang M; Zhu YZ; Xiong W; Li X; Zhou S
    Pharm Res; 2005 Nov; 22(11):1837-53. PubMed ID: 16132345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adsorption of irinotecan onto oral adsorbent AST-120 (Kremezin) for preventing delayed diarrhea.
    Hidaka M; Yamasaki K; Okumura M; Ogikubo T; Iwakiri T; Setoguchi N; Nishida K; Nagai K; Ikenoue T; Arimori K
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):321-8. PubMed ID: 16770581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice.
    Ohdo S; Makinosumi T; Ishizaki T; Yukawa E; Higuchi S; Nakano S; Ogawa N
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1383-8. PubMed ID: 9400014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats.
    Yamamoto M; Kurita A; Asahara T; Takakura A; Katono K; Iwasaki M; Ryuge S; Wada M; Onoda S; Yanaihara T; Yokoba M; Mitsufuji H; Nishii Y; Fukui T; Masuda N
    Oncol Rep; 2008 Oct; 20(4):727-30. PubMed ID: 18813810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters.
    Chu XY; Kato Y; Ueda K; Suzuki H; Niinuma K; Tyson CA; Weizer V; Dabbs JE; Froehlich R; Green CE; Sugiyama Y
    Cancer Res; 1998 Nov; 58(22):5137-43. PubMed ID: 9823324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018).
    Lam W; Jiang Z; Guan F; Hu R; Liu SH; Chu E; Cheng YC
    BMC Complement Altern Med; 2014 Dec; 14():490. PubMed ID: 25510341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1.
    Luo FR; Paranjpe PV; Guo A; Rubin E; Sinko P
    Drug Metab Dispos; 2002 Jul; 30(7):763-70. PubMed ID: 12065434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of P-glycoprotein.
    Bansal T; Awasthi A; Jaggi M; Khar RK; Talegaonkar S
    Life Sci; 2008 Aug; 83(7-8):250-9. PubMed ID: 18619980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats.
    Itoh T; Itagaki S; Sasaki K; Hirano T; Takemoto I; Iseki K
    J Pharm Pharmacol; 2004 Jun; 56(6):809-12. PubMed ID: 15231047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.